PetVivo Holdings, Inc. — fact timeline

PetVivo Holdings, Inc. issued 187,500 Units of unit to the investor for $0.80 per Unit, gross proceeds $150,000.

“On June 8, 2026, PetVivo Holdings, Inc. (the “Company,” “we,” or “us”), received gross proceeds of $150,000 pursuant to a partial exercise of the investor’s purchase option granted under that certain Subscription Agreement dated March 13, 2026 (the “Subscription Agreement”), for an aggregate investment to date of $1,150,000 in equity financing (the “Offering”). In connection with such partial exercise, the Company issued 187,500 Units at a purchase price of $0.80 per Unit, bringing the aggregate number of Units issued pursuant to the Offering to date to 1,437,500 Units.”

PetVivo Holdings, Inc. issued 1,250,000 units of unit to accredited investor for $0.80 per Unit.

“the Company issued an aggregate of 1,250,000 units (the “Units”) at a purchase price of $0.80 per Unit.”

PetVivo Holdings, Inc. issued 1,250,000 units of unit to accredited investor for $0.80 per Unit.

“PetVivo Holdings, Inc., including its wholly-owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc. (collectively, the "Company," "we," and "us"), entered into a Subscription Agreement to receive One Million Dollars ($1,000,000) of equity financing in exchange for One Million Two Hundred Fifty Thousand (1,250,000) units of the Company (the "Units") at a purchase price of $0.80 per Unit (the "Offering").”

PetVivo Holdings, Inc. issued One Million Eight Hundred Seventy-Five Thousand shares of Restricted Common Stock of common stock to the investor for One Million Five Hundred Thousand Dollars ($1,500,000) of equity financing.

“the investor received a purchase option to invest an additional One Million Five Hundred Thousand Dollars ($1,500,000) of equity financing in exchange for One Million Eight Hundred Seventy-Five Thousand shares of Restricted Common Stock of the Company pursuant to the same terms and conditions; this additional equity financing is anticipated to be received on or before June 30, 2026.”

PetVivo Holdings, Inc. issued 1,250,000 shares of Restricted Common Stock of common stock to accredited investor for $1,000,000 equity financing.

“PetVivo Holdings, Inc., including its wholly-owned subsidiaries PetVivo Animal Health and PetVivo AI, Inc., (collectively the "Company", "we" and "us") entered into a Subscription Agreement to receive One Million Dollars ($1,000,000) of equity financing in exchange for One Million Two Hundred Fifty Thousand (1,250,000) shares of Restricted Common Stock of the Company ("Shares") (the "Offering").”

PetVivo Holdings, Inc. incurred loan of $160,000 with an existing shareholder (Lender) at 10% per annum maturing December 31, 2025.

“Effective as of June 9, 2025, an existing shareholder ("Lender") of PetVivo Holdings, Inc. (the "Company") entered into a debt financing transaction that included the issuance of a promissory note having a principal amount of $160,000 (the "Promissory Note") by the Company.”

PetVivo Holdings, Inc. engaged Stephano Slack LLC as its auditor.

“ngaged Independent Registered Public Accounting Firm On April 7, 2025, the Company engaged Stephano Slack LLC (“Stephano Slack”) as the Company’s new independent registered”

Assurance Dimensions, LLC resigned as auditor of PetVivo Holdings, Inc..

“On April 1, 2025, in conjunction with its exit from providing audit services to publicly traded companies, Assurance Dimensions, LLC, also doing business as McNamara and Associates, LLC ("Assurance Dimensions") resigned from its role as independent registered public accounting firm for PetVivo Holdings, Inc. (the "Company").”

PetVivo Holdings, Inc.: Filed Certificate of Designation for Series B Convertible Preferred Stock and an amendment providing clarifications to the Company Call Option (effective 2025-03-26).

“In connection with the Offering, on March 26, 2025, the Company filed a Certificate of Designation of Rights and Preferences of Series B Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Nevada designating 5,000,000 shares of the Company’s Preferred Stock, $0.001 par value per share, as “Series B Convertible Preferred Stock,” and setting forth the voting and other powers, preferences and relative, participating, optional or other rights of the Series B Preferred Stock. An Amendment to the Certificate of Designation was filed with the Secretary of State of Nevada on March 31, 2025, which provided clarifications to the Company Call Option.”

PetVivo Holdings, Inc.: Filed Certificate of Designation for Series B Convertible Preferred Stock and amendment clarifying Company Call Option (effective 2025-03-26).

“on March 26, 2025, the Company filed a Certificate of Designation of Rights and Preferences of Series B Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Nevada designating 5,000,000 shares of the Company’s Preferred Stock, $0.001 par value per share, as “Series B Convertible Preferred Stock,” and setting forth the voting and other powers, preferences and relative, participating, optional or other rights of the Series B Preferred Stock. An Amendment to the Certificate of Designation was filed with the Secretary of State of Nevada on March 31, 2025, which provided clarifications to the Company Call Option.”

PetVivo Holdings, Inc. incurred loan of $200,000 with Michael Eldred, a member of the Board of Directors (Lender) at 12% per annum maturing on or about September 3, 2025.

“Effective as of March 6, 2025, Michael Eldred, a member of the Board of Directors (“Lender”) of PetVivo Holdings, Inc. (the “Company”), entered into a promissory note (the “Promissory Notes”), having a principal amount of $200,000. The maturity date of the Promissory Note is on or about September 3, 2025 and the interest rate is 12% per annum.”

PetVivo Holdings, Inc.: Amended and restated bylaws to reflect the name change of the subsidiary to PetVivo Animal Health, Inc.

“In addition, the By-laws of the Company were also amended and restated to reflect the name change of PetVivo, Inc. to PetVivo Animal Health, Inc.”

PetVivo Holdings, Inc.: Amended articles of incorporation to change subsidiary name from PetVivo, Inc. to PetVivo Animal Health, Inc (effective 2025-02-11).

“The Notice of Amendment to the Articles of Incorporation involving the change of company name was acknowledged by the Minnesota Secretary of State on February 11, 2025.”

Randall A. Meyer was terminated as Chief Operating Officer at PetVivo Holdings, Inc..

“By eliminating the position of COO, the Board also terminated the employment of Randall A. Meyer, effective immediately;”

James Martin departed as Chairman of the Board at PetVivo Holdings, Inc..

“On September 28, 2024, James Martin, a director and Chairman of the Board of PetVivo Holdings, Inc. (the “Company”), peacefully passed away.”

Mike Eldred was appointed as Director at PetVivo Holdings, Inc..

“Effective as of September 25, 2024, the Board of Directors of PetVivo Holdings, Inc. (the “Company”) increased the size of the Board from seven directors to eight directors and appointed Mike Eldred as a member of the Board to fill the vacancy created by the increase in size of the Board.”

PetVivo Holdings, Inc. entered into Conversion Agreement with A.L. Sarroff Fund, LLC valued at total principal amount of $300,000, plus accrued interest of $1,558 (effective 2024-04-29).

“Effective as of April 29, 2024, A.L. Sarroff Fund, LLC (the “Lender”), a greater than 10% shareholder in PetVivo Holdings, Inc. (the “Company”) entered into a note conversion agreement dated April 29, 2024 (“Conversion Agreement”) to convert the outstanding balance of a promissory note (“Note”) dated April 10, 2024, in the total principal amount of $300,000, plus accrued interest of $1,558 into 430,798 Units”

Garry Lowenthal was appointed as Chief Financial Officer at PetVivo Holdings, Inc..

“led by Garry Lowenthal, the Company’s new Chief Financial Officer.”

PetVivo Holdings, Inc. entered into Promissory Note with A.L. Sarroff Fund, LLC valued at $300,000 (effective 2024-04-10).

“s of April 10, 2024, A.L. Sarroff Fund, LLC (the “Lender”), a greater than 10% shareholder in PetVivo Holdings, Inc. (the “Company”) entered into a promissory note dated April 10, 2024 (the “Promissory Note”), in the amount”

PetVivo Holdings, Inc. received a nasdaq delisting notice notice regarding stockholders equity.

“April 1, 2024 as set forth in the March 13 Determination Letter (as defined herein). On April 8, 2024, the Company filed a request to have the Nasdaq Listing and Hearing Review Council (“Listing Council”), an appeal body for the Panel, review the decision to suspend trading of the Company’s securities as set forth in the April 5, 2024 letter (the “Second Appeal”). On April 8, 2024, the Company received confirmation from Nasdaq that it received the Second Appeal and because the matters in the Second Appeal and the Delisting Appeal (as defined below) were similar, it would consider the matter ho”

Garry Lowenthal was appointed as Chief Financial Officer at PetVivo Holdings, Inc..

“On March 8, 2024, PetVivo Holdings, Inc. (the “Company”) appointed Garry Lowenthal to serve as the Company’s Chief Financial Officer.”

PetVivo Holdings, Inc. terminated ATM Agreement with ThinkEquity LLC valued at up to $2,500,000 (effective 2024-03-07).

“PetVivo Holdings, Inc. (the “Company”) and ThinkEquity, LLC mutually agreed to terminate the ATM Sales Agreement, dated as of August 23, 2023 (the “ATM Agreement”) between the Company and with ThinkEquity LLC (the “Agent”), effective as of March 7, 2024.”

PetVivo Holdings, Inc. reported the three months ended December 31, 2023 results: revenue $595,891, net income ($0.12) per share, EPS ($0.12) per share.

“Third Quarter Financial Results For The Three Months Ended December 31, 2023 Compared to The Three Months Ended December 31, 2022 Total Revenues . Revenues were $595,891 and $510,109 for three months ended December 31, 2023 and 2022, respectively. Revenues in the three months ended December 31, 2023 consist of sales of our SpryngTM product to MWI”

Robert J. Folkes departed as Chief Financial Officer at PetVivo Holdings, Inc..

“he will be resigning as Chief Financial Officer (“CFO”) of the Company, effective as of February 2, 2024.”

PetVivo Holdings, Inc. entered into Distribution Agreement with Covetrus North America, LLC valued at Non-exclusive distributor appointment with right to promote, market, distribute, and sell the Compan (effective 2024-01-01).

“On December 18, 2023, PetVivo Holdings, Inc. (the “Company”) entered into a Distribution Agreement (the “Agreement” or “Distribution Agreement”) with Covetrus North America, LLC (“Covetrus”), which has an effective date of January 1, 2024.”

PetVivo Holdings, Inc. amended First Amendment to Distribution Services Agreement with MWI Veterinary Supply Company (effective 2023-12-13).

“PetVivo Holdings, Inc. (the “Company”) entered into a First Amendment to Distribution Services Agreement (the “First Amendment”) with MWI Veterinary Supply Company (“MWI”) on December 13, 2023”

PetVivo Holdings, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 17, 2023, PetVivo Holdings, Inc. (the “Company”) received written notice (“ Notice ”) from the Nasdaq Stock Market (“ Nasdaq ”) stating that the Company no longer complies with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on The Nasdaq Capital Market because the Company’s stockholders’ equity, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, has fallen below $2.5 million. In addition, the Company does not meet the alternative compliance standards relating to the mark”

PetVivo Holdings, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-11-17 meeting.

“The ratification of the appointment of Assurance Dimensions, Inc. as the Company’s independent registered public accounting firm for the year ending March 31, 2024, was approved by the following final voting results:”

PetVivo Holdings, Inc. shareholders approved Election of Directors at the 2023-11-17 meeting.

“The director nominees proposed by the Board of Directors of the Company (the “Board”) were elected to serve as members of the Board until the next annual meeting of stockholders and until their successors are duly elected and qualified by the following final voting results:”

PetVivo Holdings, Inc. reported six months ended September 30, 2023 results: revenue $324,549, net income $6,554,730, EPS ($0.53) per share.

“of shares outstanding was 12,987,641 and 10,053,463 for the three months ended September 30, 2023 and 2022, respectively. Year to Date Financial Results Revenues . Revenues were $324,549 for six the months ended September 30, 2023 compared to revenues of $281,454 in the six months ended September 30, 2022. Revenues in the six months ended September 30, 2023”

PetVivo Holdings, Inc. reported three months ended September 30, 2023 results: revenue $207,366, net income $3,661,153, EPS ($0.28) per share.

“Second Quarter Financial Results For The Three Months Ended September 30, 2023 Compared to The Three Months Ended September 30, 2022 Total Revenues . Revenues were $207,366 and $223,280 for three months ended September 30, 2023 and 2022, respectively. Revenues in the three months ended September 30, 2023 consist of sales of our SpryngTM product to”

PetVivo Holdings, Inc. entered into Sales Agreement with ThinkEquity LLC valued at up to $2,500,000 (effective 2023-08-23).

“On August 23, 2023, PetVivo Holdings, Inc. (the “Company”), entered into an ATM Sales Agreement (the “Sales Agreement”) with ThinkEquity LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares (the “Shares”) of the Company’s common stock (the “Common Stock”), having an aggregate offering price of up to $2,500,000, subject to the terms and conditions of the Sales Agreement.”

PetVivo Holdings, Inc. entered into Convertible Debenture Conversion Agreements with three debenture holders valued at $550,000 (effective 2023-08-11).

“On August 11, 2023, PetVivo Holdings, Inc. (the “Company”) entered into Convertible Debenture Conversion Agreements (“Conversion Agreements”) with three debenture holders (“Debenture Holders”) who advanced an aggregate of $550,000 to the Company pursuant to convertible debentures (“Convertible Debentures”) dated July 26, 2023.”

PetVivo Holdings, Inc. reported three months ended June 30, 2023 results: revenue $117,183, net income $2,893,577 or ($0.25) per share, EPS ($0.25) per share.

“university study and other third-party studies prior to including a product in their catalog of products.” First Quarter Financial Results Total Revenues . Revenues were $117,183 and $58,174 for three months ended June 30, 2023 and 2022, respectively. Revenues in the three months ended June 30, 2023, consist of sales of our SpryngTM products to MWI”

PetVivo Holdings, Inc. entered into Securities Purchase Agreement with two accredited investors valued at 1,200,002 shares of common stock at $1.50 per share and warrants to purchase 1,200,002 shares (effective 2023-08-04).

“On August 4, 2023, PetVivo Holdings, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a two accredited investors (the “Investor”), pursuant to which the Company agreed to issue and sell to the Investors in a registered direct offering (the “Registered Offering”) 1,200,002 shares (“Registered Shares”) of the Company’s common stock (the “Common Stock”) at a price of $1.50 per share.”

PetVivo Holdings, Inc. incurred convertible notes of $550,000 with three accredited investors at 10% per annum maturing January 26, 2024.

“On July 27, 2023, PetVivo Holdings, Inc. (the “Company”) issued convertible promissory notes (“Convertible Notes”) in the aggregate amount of $550,000 to three accredited investors pursuant to debenture subscription agreements (“Debenture Subscription Agreement”). The Convertible Notes mature on January 26, 2024 (the “Maturity Date”), bear interest at a rate of 10% per annum and automatically convert into shares of the Company’s common stock which are restricted under Rule 144 of the Securities Act of 1933, as amended, on the earlier of (i) the Maturity Date or (ii) upon the occurrence of certain events prior to the Maturity Date, including, without limitation, a Qualified Financing, Sale or Public Offering (as such terms are defined in the Convertible Notes).”

PetVivo Holdings, Inc. reported fiscal year ended March 31, 2023 results: revenue $917,162, net income $8,717,608, EPS ($0.85 per share).

“Total Revenues . Revenues were $917,162 in fiscal 2023 compared to $115,586 for fiscal 2022. Revenues in fiscal 2023 consisted of sales of our SpryngTM products to MWI of $636,345 and to veterinary clinics in the amount of $280,817. In fiscal 2022, our revenues of $115,586 consisted of sales to veterinary clinics. The increase in our revenues in fiscal 2023 is due to sales to MWI pursuant to our Distribution Agreement and increased sales to veterinary clinics. Total Cost of Sales . Cost of sales was $526,817 in fiscal 2023 compared to $201,154 for fiscal 2022. Cost of sales includes product costs related to the sale of our SpryngTM products and labor and overhead costs. The increase in cost of sales in fiscal 2023 is due to the increased sales to MWI pursuant to our Distribution Agreement and increased sales to veterinary clinics. Operating Expenses . Operating expenses increased to $9,123,797 in fiscal 2023 compared to $4,970,960 in fiscal 2022. Operating expenses consisted of general”

PetVivo Holdings, Inc. entered into Finders Fee Agreement with Bancroft Capital, LLC valued at $63,456.25 (effective 2023-03-28).

“the Company engaged the Broker, a broker-dealer registered with the SEC and a member of FINRA, pursuant to a finder’s agreement dated March 28, 2023 (“Finders Fee Agreement”) to introduce it to investors.”

PetVivo Holdings, Inc. entered into Purchase Agreements with investors valued at $2,182,355 (effective 2023-04-17).

“the Company entered into securities purchase agreement and other confirmation of ownership with investors on April 17, 2023 (collectively, the “Purchase Agreements”), pursuant to which the Company agreed to issue and sell an aggregate of 793,585 shares of its common stock (the “Registered Shares”) in a registered direct offering (the “Registered Offering”) at a purchase price of $2.75 per share.”

PetVivo Holdings, Inc. entered into Finders Fee Agreement with Bancroft Capital, LLC valued at $63,456.25 (effective 2023-03-28).

“The Company engaged Bancroft, a broker-dealer registered with the SEC and a member of FINRA, pursuant to a finder’s agreement dated March 28, 2023 (“Finders Fee Agreement”) to introduce it to investors.”

PetVivo Holdings, Inc. entered into Purchase Agreement with certain investors valued at $2,152,355 (effective 2023-04-17).

“PetVivo Holdings, Inc. (the “Company”) entered into certain documents, including a securities purchase agreement dated April 17, 2023 and/or other confirmation of purchase (the “Purchase Agreement”), with certain investors”

Spencer Breithaupt was appointed as Director at PetVivo Holdings, Inc..

“Effective as of April 14, 2023, the Board of Directors of PetVivo Holdings, Inc. (the “Company”) increased the size of the Board from seven directors to eight directors and appointed Spencer Breithaupt as a member of the Board to fill the vacancy created by the increase in size of the Board.”

PetVivo Holdings, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“February 17, 2023, PetVivo Holdings, Inc. (the “Company”) received written notice (“ Notice ”) from the Nasdaq Stock Market (“ Nasdaq ”) stating that the Company no longer complies with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on The Nasdaq Capital Market because the Company’s stockholders’ equity, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2022, has fallen below $2.5 million. The Notice also indicates that the Company does not meet the alternative compliance standards rel”

PetVivo Holdings, Inc. reported third fiscal quarter ended December 31, 2022 results: revenue $510,109, net income $2,311,618 or ($0.23) per share, EPS ($0.23) per share.

“the third quarter of 2023 and recent weeks include the following (all comparisons are with the three months ended December 31, 2021, unless otherwise indicated): ● Revenues of $510,109 for the three months ended December 31, 2022, compared to revenues of $51,004 in the three months ended December 31, 2021. ● Net revenues of $456,502 was from shipments of”

PetVivo Holdings, Inc. amended Amended Purchase Agreement with certain accredited investors valued at $1,415,225.52 (effective 2023-01-05).

“On January 5, 2023, PetVivo Holdings, Inc. (the “Company”) entered into an amended and restated securities purchase agreement with certain accredited investors (the “Amended Purchase Agreement”), pursuant to which the Company agreed to issue and sell an aggregate of 610,011 Registered Shares in the Registered Offering at a purchase price of $2.32 per share.”

PetVivo Holdings, Inc. entered into Lease with Dewey AL L.L.C. and Dewey MS L.L.C. (effective 2023-01-10).

“On January 10, 2023, PetVivo Holdings, Inc. (the “Company”) entered into a lease agreement (the “Lease”) with Dewey AL L.L.C. and Dewey MS L.L.C., each a Minnesota limited liability company (collectively, as tenants in common, the “Landlord”), for certain property located in Suite D of the building located at 5555 West 78 th Street, Edina, Minnesota (the “Building”), that will include a new manufacturing facility, shared dock space and administrative offices having approximately 14,073 square feet (the “Facility”).”

PetVivo Holdings, Inc. entered into Purchase Agreement with certain accredited investors valued at approximately $1.3 million (effective 2023-01-05).

“On January 5, 2023, PetVivo Holdings, Inc. (the “Company”) entered into a securities purchase agreement with certain accredited investors (the “Purchase Agreement”), pursuant to which the Company agreed to sell and issue an aggregate of 575,011 shares of its common stock (the “Registered Shares”) in a registered direct offering (the “Registered Offering”) of the Company’s common stock (the “Common Stock”) at a purchase price of $2.32 per share.”

PetVivo Holdings, Inc. reported the second quarter ended September 30, 2022 results: revenue $223,280, net income $2,111,589, EPS ($0.21) per share.

“quarter of fiscal year 2023 and recent weeks include the following (all comparisons are with the second quarter of fiscal year 2022, unless otherwise indicated): ● Revenues of $223,280 for the three months ended September 30, 2022, compared to revenues of $4,977 in the three months ended September 30, 2021; ● Net revenue of $118,264 was from shipments of”

James Martin was named as Chairman of the Board at PetVivo Holdings, Inc..

“The Board made other changes, including naming James Martin, as the new Chairman of the Board”

Leslie Coolidge was appointed as Director at PetVivo Holdings, Inc..

“the Board of Directors (the “Board”) of the Company appointed Rob Costantino and Leslie Coolidge to the Board”